



PRESS RELEASE

Profil Institute to Present at the European Association for the Study of Diabetes Annual Meeting

Profil Institute the Only Clinical Research Institute Exhibiting at Annual Meeting, Strengthening Company's Position as a Leading Specialized Provider of Phase I Clinical Trials in Diabetes

SAN DIEGO, September 12, 2011 – Profil® Institute for Clinical Research, Inc., a specialized contract research institute optimizing early phase diabetes, obesity and cardiometabolic drug development, will present key clinical and experimental diabetes and insulin-related research at the European Association for the Study of Diabetes (EASD) 47th Annual Meeting being held September 12 - 16 in Lisbon, Portugal. Profil Institute is the only clinical research institute exhibiting at the EASD Annual Meeting, strengthening the company's position as the leading specialized provider of early phase clinical trials for diabetes drug and device development.

Profil Institute's Poster Presentations

- **Poster #1043: Accelerated absorption and reduced glycaemic variability in type 1 diabetes mellitus patients by human hyaluronidase-facilitated coinfusion of a prandial insulin analogue**
M. Hompesch, D.B. Muchmore, L. Morrow, D.E. Vaughn
Tuesday, September 13, 1:30pm – 2:30pm, Poster Event B, PS 092 Insulin therapy in type 1 diabetes
- **Poster #884: Intact central counter-regulatory responses to hypoglycaemia induced by oral glucokinase activators in comparison with insulin infusion in healthy male volunteers**
E. Norjavaara, H. Ericsson, F. Sjoberg, M. Leonsson-Zachrisson, L. Morrow, M. Hompesch
Wednesday, September 14, 12:30pm – 1:30pm, Poster Event C, PS 075 The three G's: Glucokinase, Glucagon receptors and G-protein coupled receptors
- **Poster #885: AZD1656, a novel glucokinase activator, lowers plasma glucose in patients with type 2 diabetes**
L. Morrow, M. Leonsson-Zachrisson, H. Ericsson, M. Wollbratt, M. Knutsson, M. Hompesch, E. Norjavaara
Wednesday, September 14, 12:30pm – 1:30pm, Poster Event C, PS 075 The three G's: Glucokinase, Glucagon receptors and G-protein coupled receptors

About Profil® Institute for Clinical Research, Inc.

Profil Institute is world-renowned as a Center of Excellence for diabetes and obesity early phase clinical research. The company's advances in early phase drug research and its specific focus on diabetes, obesity and cardio-metabolic diseases as it relates to the diabetic patient population have led

Profil Institute to be the most highly regarded clinical research institute for early phase diabetes drug trials.

To date, Profil Institute has been involved with almost every clinically promising drug category and device development in diabetes and in more than 140 clinical studies since the company's inception in 2004. Contributing to Profil Institute's success is that the company is recognized as the leader in automated glucose clamps, considered the "Gold Standard" for the evaluation of anti-diabetic drugs and devices. The company's key scientists hail from academic centers including the WHO Collaborating Center of Diabetes at the Heinrich-Heine University of Düsseldorf, Columbia University, University of Michigan and Harvard University. For more information visit www.profilinstitute.com.

For further information please contact:

Dennis DeRosia

Director Business Development

bd@profilinstitute.com